Description: Gene therapy is a quickly evolving field and will continue to grow as a risk concern for many health plans, stop loss insurers and reinsurers. Currently, there are only two approved gene therapies in the U.S., but that number is expected to escalate starting in the fall of 2022. Revisit the experience plans have had with the first two gene therapies, discuss plan design and network considerations in light of gene therapy, and discuss the actual composition of the near-term pipeline along with a range of modeled financial impacts and considerations for payers.

Description: The Casualty Actuarial Society (CAS), the Society of Actuaries (SOA) and the Society of Insurance Research (SIR) started developing research addressing diversity, equity and inclusion (DEI) topics. Join panelists as they briefly present an overview of their organization's DEI research and share their perspectives on common challenges facing all the stages of this research: - Planning relevant and timely research with a long timeline. - Getting appropriate data and resources to support your research. - Communicating research on topics that may be controversial.

Description: Are you interested in learning about technical changes to the risk adjustment methodology, Texas implementing effective rate review and premium alignment rules, new rules on standard benefits and network adequacy? Discover some of the reasons why the 2023 ACA marketplace will look much different in the first year of the Biden administration setting the tone with annual ACA rules. Listen to a panel of consulting actuaries and the Chief Actuary from the Texas Department of Insurance who are deeply involved in state and federal policy, risk adjustment methodology, and continuous monitoring of changing market dynamics. Explore new federal rules, efforts to strengthen enforcement of rating compliance, current considerations in risk adjustment methodology, and the ACA market outlook for 2023 and 2024.

Description: Risk Adjustment continues to be a hot topic in Health Insurance since its emergence. This mechanism came into being as a means of reducing the risk of selection, particularly in marketplaces where underwriting is not allowed, and rating factors are significantly restricted. Risk adjustment serves to adjust premiums to reflect the risk of individual members or overall members as a whole within a particular cohort of a health plan. Risk adjustment is not perfect, as it does not perfectly predict future costs or perfectly adjust for the differences in expected costs. Different marketplaces have different challenges with risk adjustment.

Description: Discussion of recent developments in the taxation of noncoordinated benefits such as fixed indemnity, hospital indemnity, and specified disease insurance policies. Developments include a recent Chief Counsel Advice Memorandum and proposed triagency rulemaking that would impact non coordinated benefits.

Description: The momentum in value-based care has produced an opportunity for actuaries to become pioneers in health care

Description: As actuaries, we're trained to see patterns in numbers and to design solutions that mitigate risk. While quantitative analysis and modeling are critical actuarial tools, looking at the numbers alone can lead to insurance products that don't succeed in the real world the way math says they should. With new digital technologies surfacing in the insurance space, we have more data at our fingertips than ever before, leading to a higher focus on doing quantitative research within insurance product design. Take back a step from quantitative research and discover qualitative research methodologies into your product development process to design solutions that meet real needs in the market. In a nutshell, qualitative research can surface issues early and help you answer questions such as: Can we really sell this product in the market? Why would someone buy this? How widespread is the need? How could your product be a solution you didn't intend?

Description: Long-duration targeted improvements (LDTI) will have unique consequences for long-term care and disability income. Discuss how to address these issues and learn more aboutboth standalone and combination LTC contracts. Understand the impact of LDTI on DAC, policies which previously held zero active life reserves, and allocation of IBNR to cohorts. By attending the session, you will: - Be able to create and defend accounting policies and to implement actuarial models consistent with the new U.S. GAAP accounting rules.

Description: Pharmacy prices are top of mind for many consumers, policymakers, and payers. There are many proposals out there about ways to reduce pharmacy costs, almost all of which involve price controls. Is that the right move? What about the unintended consequences of such regulation? Will fewer life-saving drugs be developed including fewer drugs that improve the quality of life? Are better financing alternatives out there? Explore the concept of value-based reimbursement for pharmacy prices, including the lessons learned from applying value-based concepts to hospital and physician value-based financing.

Description: This article is intended to inform readers about the current state of mental health and health care in the US, as were it's heading moving forward.